Amedisys (AMED) Lowered to “Hold” at ValuEngine

ValuEngine lowered shares of Amedisys (NASDAQ:AMED) from a buy rating to a hold rating in a research note released on Tuesday, ValuEngine reports.

Several other analysts have also recently commented on the company. BidaskClub raised Amedisys from a buy rating to a strong-buy rating in a research report on Thursday, February 14th. Benchmark cut Amedisys from a buy rating to a hold rating and set a $136.64 target price for the company. in a research report on Tuesday, February 5th. Zacks Investment Research raised Amedisys from a hold rating to a buy rating and set a $151.00 target price for the company in a research report on Thursday, February 7th. Barclays raised their target price on Amedisys from $115.00 to $120.00 and gave the stock an equal weight rating in a research report on Thursday, March 21st. Finally, Craig Hallum decreased their target price on Amedisys from $132.00 to $124.00 and set a hold rating for the company in a research report on Friday, March 1st. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $125.90.

Shares of NASDAQ AMED opened at $108.34 on Tuesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.91 and a current ratio of 0.91. The firm has a market capitalization of $3.47 billion, a P/E ratio of 29.85, a P/E/G ratio of 1.39 and a beta of 1.33. Amedisys has a 52-week low of $71.74 and a 52-week high of $140.91.

Amedisys (NASDAQ:AMED) last issued its earnings results on Tuesday, April 30th. The health services provider reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.89 by $0.22. The business had revenue of $467.34 million for the quarter, compared to analysts’ expectations of $460.83 million. Amedisys had a return on equity of 28.25% and a net margin of 7.14%. The company’s quarterly revenue was up 17.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.79 EPS. As a group, research analysts expect that Amedisys will post 4.08 EPS for the current fiscal year.

In other news, Director Bruce D. Perkins acquired 2,500 shares of Amedisys stock in a transaction that occurred on Wednesday, May 15th. The stock was purchased at an average price of $111.84 per share, with a total value of $279,600.00. Following the completion of the transaction, the director now owns 22,088 shares in the company, valued at $2,470,321.92. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider David L. Kemmerly sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $118.20, for a total value of $591,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,281 shares of company stock valued at $2,160,243. Insiders own 2.90% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Navellier & Associates Inc raised its holdings in Amedisys by 148.7% during the fourth quarter. Navellier & Associates Inc now owns 17,558 shares of the health services provider’s stock valued at $2,056,000 after buying an additional 10,499 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Amedisys by 15.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,900 shares of the health services provider’s stock valued at $223,000 after buying an additional 251 shares in the last quarter. Rhumbline Advisers raised its holdings in Amedisys by 20.4% during the fourth quarter. Rhumbline Advisers now owns 79,058 shares of the health services provider’s stock valued at $9,258,000 after buying an additional 13,414 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Amedisys by 146.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 49,306 shares of the health services provider’s stock valued at $5,774,000 after buying an additional 29,262 shares in the last quarter. Finally, Martingale Asset Management L P raised its holdings in Amedisys by 12.2% during the fourth quarter. Martingale Asset Management L P now owns 23,006 shares of the health services provider’s stock valued at $2,695,000 after buying an additional 2,500 shares in the last quarter. Institutional investors own 91.71% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Recommended Story: Outstanding Shares

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.